02.04.2013 - Sanofi will expand its current 4% market stake in Vietnam. Between now and 2015, the French drug major will invest US$75m in a production plant.
The plant, which will be operative by 2015, is designed to meet the raising demand for pharmaceuticals in fast-growing Asian populations such as China, Indonesia and Vietnam. It will have an initial capacity of 90 million units per year, which may be later extended to 150 million units, according to the company.
Sanofi currently runs two plants in Ho Chi Minh City at full capacity, according to Sanofi CEO Chris Viehbacher. “Asia continues to grow and it seems to be less affected by the European economic difficulty,” said the company's head. The rise of income and urbanisation in the region will give people more access to health care. Currently sales from Sanofi’s Vietnamese plants are growing 25% annually, creating more than US$128m annually in Vietnam alone. The company, which exports just 20% of the drugs manufactured in the country, will now expand its production capacity to create an export platform for the Southeast Asian region.
In 2012 Sanofi delivered almost one third of its US$35bn sales in emerging markets, US$4,9bn of that with diabetes drugs alone, where the French are world market leader. Asian countries contribute to more than 60% of the world’s diabetic population and their prevalence of diabetes is increasing. Asians have a strong ethnic and genetic predisposition for diabetes and have lower thresholds for the environmental risk factors. As a result, they develop diabetes at a younger age and at a lower body mass index and waist circumference when compared with the Western population.
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.